肝转移瘤临床中较为常见,35%～50%来源于腹部肿瘤。肝转移瘤有较为特异的影像学特征。近年来,手术、介入、立体定向放疗在肝转移瘤治疗方面的应用得到了延伸。对于大肠癌肝转移,全身化疗仍占主导地位。一线方案包括FOLFOX、FOLFIRI、5FU/叶酸、CAPOX、IFL联合贝伐单抗等方案,二线治疗包括FOLFOX、FOLFIRI、单药伊立替康、伊立替康联合西妥昔单抗等,AVASTIN、ERBITUX等分子靶向治疗处于研究的最前沿,改善了晚期结肠癌患者的生存指标,确定了其在该领域治疗的主导地位。 Liver metastases are more common in clinical, 35% to 50% from abdominal tumors. Liver metastases have more specific imaging features. In recent years, surgery, intervention, stereotactic radiotherapy in the treatment of liver metastases has been extended. For liver metastases of colorectal cancer, systemic chemotherapy still dominates. First-line programs include FOLFOX, FOLFIRI, 5FU / folic acid, CAPOX, IFL combined with bevacizumab and other programs, second-line treatment, including FOLFOX, FOLFIRI, monotherapy irinotecan, irinotecan combined with cetuximab and so on, AVASTIN, ERBITUX Molecular targeted therapies are at the forefront of research, improving the survival of patients with advanced colon cancer and determining their dominance in this area.